259 related articles for article (PubMed ID: 22608054)
1. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009-2010.
Kirkcaldy RD; Augostini P; Asbel LE; Bernstein KT; Kerani RP; Mettenbrink CJ; Pathela P; Schwebke JR; Secor WE; Workowski KA; Davis D; Braxton J; Weinstock HS
Emerg Infect Dis; 2012 Jun; 18(6):939-43. PubMed ID: 22608054
[TBL] [Abstract][Full Text] [Related]
2. Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population.
Krashin JW; Koumans EH; Bradshaw-Sydnor AC; Braxton JR; Evan Secor W; Sawyer MK; Markowitz LE
Sex Transm Dis; 2010 Jul; 37(7):440-4. PubMed ID: 20351623
[TBL] [Abstract][Full Text] [Related]
3.
Mtshali A; Ngcapu S; Govender K; Sturm AW; Moodley P; Joubert BC
Microbiol Spectr; 2022 Aug; 10(4):e0091222. PubMed ID: 35863010
[TBL] [Abstract][Full Text] [Related]
4. Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations.
Seña AC; Bachmann LH; Hobbs MM
Expert Rev Anti Infect Ther; 2014 Jun; 12(6):673-85. PubMed ID: 24555561
[TBL] [Abstract][Full Text] [Related]
5. The genetic diversity of metronidazole susceptibility in Trichomonas vaginalis clinical isolates in an Egyptian population.
Abdel-Magied AA; El-Kholya EI; Abou El-Khair SM; Abdelmegeed ES; Hamoudaa MM; Mohamed SA; El-Tantawy NL
Parasitol Res; 2017 Nov; 116(11):3125-3130. PubMed ID: 28956167
[TBL] [Abstract][Full Text] [Related]
6. In vitro effect of tinidazole and furazolidone on metronidazole-resistant Trichomonas vaginalis.
Narcisi EM; Secor WE
Antimicrob Agents Chemother; 1996 May; 40(5):1121-5. PubMed ID: 8723451
[TBL] [Abstract][Full Text] [Related]
7. [Investigation of in vitro metronidazole resistance in the clinical isolates of Trichomonas vaginalis].
Ertabaklar H; Yaman Karadam S; Malatyalı E; Ertuğ S
Mikrobiyol Bul; 2016 Oct; 50(4):552-558. PubMed ID: 28124960
[TBL] [Abstract][Full Text] [Related]
8. Trichomonas vaginalis Virus Among Women With Trichomoniasis and Associations With Demographics, Clinical Outcomes, and Metronidazole Resistance.
Graves KJ; Ghosh AP; Schmidt N; Augostini P; Secor WE; Schwebke JR; Martin DH; Kissinger PJ; Muzny CA
Clin Infect Dis; 2019 Nov; 69(12):2170-2176. PubMed ID: 30768180
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Testing of Trichomonas vaginalis Drug Susceptibility: Evaluation of Minimal Lethal Concentrations for Metronidazole and Tinidazole That Correspond With Treatment Failure.
Augostini P; Bradley ELP; Raphael BH; Secor WE
Sex Transm Dis; 2023 Jun; 50(6):370-373. PubMed ID: 36849257
[TBL] [Abstract][Full Text] [Related]
10. Utility of antimicrobial susceptibility testing in Trichomonas vaginalis-infected women with clinical treatment failure.
Bosserman EA; Helms DJ; Mosure DJ; Secor WE; Workowski KA
Sex Transm Dis; 2011 Oct; 38(10):983-7. PubMed ID: 21934577
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of the literature on mechanisms of 5-nitroimidazole resistance in
Graves KJ; Novak J; Secor WE; Kissinger PJ; Schwebke JR; Muzny CA
Parasitology; 2020 Nov; 147(13):1383-1391. PubMed ID: 32729451
[TBL] [Abstract][Full Text] [Related]
12. Mycoplasma hominis infection of Trichomonas vaginalis is not associated with metronidazole-resistant trichomoniasis in clinical isolates from the United States.
Butler SE; Augostini P; Secor WE
Parasitol Res; 2010 Sep; 107(4):1023-7. PubMed ID: 20652315
[TBL] [Abstract][Full Text] [Related]
13. A case of metronidazole-resistant Trichomonas vaginalis in pregnancy.
Forbes GL; Drayton R; Forbes GD
Int J STD AIDS; 2016 Sep; 27(10):906-8. PubMed ID: 26384945
[TBL] [Abstract][Full Text] [Related]
14. In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis.
Crowell AL; Sanders-Lewis KA; Secor WE
Antimicrob Agents Chemother; 2003 Apr; 47(4):1407-9. PubMed ID: 12654679
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of netropsin dihydrochloride against the viability, cytopathogenicity and hemolytic activity of Trichomonas vaginalis clinical isolates.
Abou Gamra MM; Kamel HH; Ezz Eldin HM; Taha Zahran FM
J Infect Chemother; 2019 Dec; 25(12):955-964. PubMed ID: 31189504
[TBL] [Abstract][Full Text] [Related]
16. High rates of double-stranded RNA viruses and Mycoplasma hominis in Trichomonas vaginalis clinical isolates in South Brazil.
da Luz Becker D; dos Santos O; Frasson AP; de Vargas Rigo G; Macedo AJ; Tasca T
Infect Genet Evol; 2015 Aug; 34():181-7. PubMed ID: 26160539
[TBL] [Abstract][Full Text] [Related]
17. Treatment of metronidazole-resistant Trichomonas vaginalis with tinidazole: case reports of three patients.
Hager WD
Sex Transm Dis; 2004 Jun; 31(6):343-5. PubMed ID: 15167642
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic.
Schmid G; Narcisi E; Mosure D; Secor WE; Higgins J; Moreno H
J Reprod Med; 2001 Jun; 46(6):545-9. PubMed ID: 11441678
[TBL] [Abstract][Full Text] [Related]
19.
Ghosh AP; Aycock C; Schwebke JR
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29439963
[TBL] [Abstract][Full Text] [Related]
20. Trichomonas vaginalis in selected U.S. sexually transmitted disease clinics: testing, screening, and prevalence.
Meites E; Llata E; Braxton J; Schwebke JR; Bernstein KT; Pathela P; Asbel LE; Kerani RP; Mettenbrink CJ; Weinstock HS
Sex Transm Dis; 2013 Nov; 40(11):865-9. PubMed ID: 24113409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
